Orchestra BioMed Holdings, Inc. Selling, General and Administrative Expense
Orchestra BioMed Holdings, Inc. (OBIO) reported Selling, General and Administrative Expense of $5.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-10
- Orchestra BioMed Holdings, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $5.83M, a 6.94% decline year-over-year.
- Orchestra BioMed Holdings, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $6.37M, a 1.76% increase year-over-year.
- Orchestra BioMed Holdings, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $7.29M, a 23.52% increase year-over-year.
- Orchestra BioMed Holdings, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $7.10M, a 25.27% increase year-over-year.
- Orchestra BioMed Holdings, Inc. selling, general and administrative expense for fiscal 2025 was $26.91M, a 12.47% increase from fiscal 2024.
- Orchestra BioMed Holdings, Inc. selling, general and administrative expense for fiscal 2024 was $23.93M, a 18.13% increase from fiscal 2023.
- Orchestra BioMed Holdings, Inc. selling, general and administrative expense for fiscal 2023 was $20.26M, a 44.35% increase from fiscal 2022.
- Orchestra BioMed Holdings, Inc. selling, general and administrative expense for fiscal 2022 was $14.03M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.83M 10-Q · filed 2026-08-10 | $12.20M 10-Q · filed 2026-08-10 | $19.49M derived: sum of 3 quarters · filed 2026-08-10 | $26.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $6.37M 10-Q · filed 2026-05-12 | $13.66M derived: sum of 2 quarters · filed 2026-05-12 | $20.76M derived: sum of 3 quarters · filed 2026-05-12 | $27.02M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $7.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $14.39M derived: sum of 2 quarters · filed 2026-03-12 | $20.65M derived: sum of 3 quarters · filed 2026-08-10 | $26.91M 10-K · filed 2026-03-12 |
| 2025-09-30 | $7.10M 10-Q · filed 2025-11-10 | $13.36M derived: sum of 2 quarters · filed 2026-08-10 | $19.63M 10-Q · filed 2025-11-10 | $25.53M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $6.26M 10-Q · filed 2026-08-10 | $12.53M 10-Q · filed 2026-08-10 | $18.43M derived: sum of 3 quarters · filed 2026-08-10 | $24.09M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $6.26M 10-Q · filed 2026-05-12 | $12.16M derived: sum of 2 quarters · filed 2026-05-12 | $17.83M derived: sum of 3 quarters · filed 2026-05-12 | $24.30M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $5.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $11.57M derived: sum of 2 quarters · filed 2026-03-12 | $18.03M derived: sum of 3 quarters · filed 2026-03-12 | $23.93M 10-K · filed 2026-03-12 |
| 2024-09-30 | $5.67M 10-Q · filed 2025-11-10 | $12.13M derived: sum of 2 quarters · filed 2025-11-10 | $18.03M 10-Q · filed 2025-11-10 | $22.21M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $6.47M 10-Q · filed 2025-08-12 | $12.36M 10-Q · filed 2025-08-12 | $16.55M derived: sum of 3 quarters · filed 2025-08-12 | $22.89M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $5.90M 10-Q · filed 2025-05-12 | $10.08M derived: sum of 2 quarters · filed 2025-05-12 | $16.43M derived: sum of 3 quarters · filed 2025-05-12 | $21.74M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $10.53M derived: sum of 2 quarters · filed 2025-03-31 | $15.85M derived: sum of 3 quarters · filed 2025-03-31 | $20.26M 10-K · filed 2025-03-31 |
| 2023-09-30 | $6.34M 10-Q · filed 2024-11-12 | $11.66M derived: sum of 2 quarters · filed 2024-11-12 | $16.07M 10-Q · filed 2024-11-12 | $19.41M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $5.32M 10-Q · filed 2024-08-12 | $9.73M 10-Q · filed 2024-08-12 | $13.06M derived: sum of 3 quarters · filed 2024-08-12 | $18.34M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $4.41M 10-Q · filed 2024-05-13 | $7.75M derived: sum of 2 quarters · filed 2024-05-13 | $13.02M derived: sum of 3 quarters · filed 2024-05-13 | $15.97M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $8.61M derived: sum of 2 quarters · filed 2024-03-27 | $11.56M derived: sum of 3 quarters · filed 2024-03-27 | $14.03M 10-K · filed 2024-03-27 |
| 2022-09-30 | $5.28M 10-Q · filed 2023-11-13 | $8.22M derived: sum of 2 quarters · filed 2023-11-13 | $10.70M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $2.95M 10-Q · filed 2023-08-10 | $5.42M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $2.48M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |